erythrodysesthesia syndrome

e·ryth·ro·dys·es·the·si·a syn·drome

tingling sensation of the palms and soles, progressing to severe pain and tenderness with erythema and edema; caused by continuous infusion therapy.
References in periodicals archive ?
Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med.
Due to grade 3 palmar-plantar erythrodysesthesia syndrome occurring 12 months after dosing, the dose was reduced to 1000 mg.
The most common side effects of Lenvima were high blood pressure (hypertension), fatigue, diarrhea, joint and muscle pain (arthralgia/myalgia), decreased appetite, decreased weight, nausea, inflammation of the lining of the mouth (stomatitis), headache, vomiting, excess protein in the urine (proteinuria), swelling and pain in the palms, hands and/or the soles of the feet (palmar-plantar erythrodysesthesia syndrome), abdominal pain and changes in voice volume or quality (dysphonia).
20 April 2011 - Spanish biopharmaceutical company Advancell has announced the initiation of a clinical Phase IIb study of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side effect of chemotherapy.

Full browser ?